BTK inhibitors

Bruton's tyrosine kinase (BTK) inhibitors represent a pivotal class of targeted small molecule drugs used primarily in the treatment of B-cell malignancies and autoimmune diseases. Their development is rooted in the understanding of BTK’s role in the B-cell receptor (BCR) signaling pathway. Dysregulation of this pathway contributes to the proliferation and survival of malignant B-cells, and BTK inhibitors are designed to disrupt this signaling.

---

1. Mechanism of Action

Bruton's tyrosine kinase is a non-receptor cytoplasmic tyrosine kinase involved in signal transduction from the B-cell receptor (BCR) complex. BTK is essential for:

• B-cell development

• B-cell proliferation

• B-cell survival

• B-cell maturation and differentiation

Upon activation of the BCR, BTK mediates phosphorylation cascades that lead to the activation of downstream pathways including:

• NF-κB

• MAPK/ERK

• PI3K-AKT

BTK inhibitors work by binding to the active site of BTK and preventing its phosphorylation activity. There are two types:

• Covalent BTK inhibitors: Bind irreversibly to Cys481 of BTK (e.g., ibrutinib, acalabrutinib, zanubrutinib)

• Non-covalent BTK inhibitors: Bind reversibly and do not depend on Cys481 (e.g., pirtobrutinib, fenebrutinib)

---

2. Approved BTK Inhibitors

Several BTK inhibitors have gained FDA and EMA approval, particularly for hematological malignancies:

1. Ibrutinib

   • First-in-class BTK inhibitor

   • Irreversibly binds Cys481

   • Approved for:

     • Chronic lymphocytic leukemia (CLL)

     • Mantle cell lymphoma (MCL)

     • Waldenström's macroglobulinemia

     • Marginal zone lymphoma

     • Chronic graft-versus-host disease

   • Brand name: Imbruvica

2. Acalabrutinib

   • More selective for BTK than ibrutinib

   • Reduced off-target effects

   • Approved for:

     • CLL

     • MCL

   • Brand name: Calquence

3. Zanubrutinib

   • Highly selective BTK inhibitor

   • Designed for better safety and CNS penetration

   • Approved for:

     • Waldenström's macroglobulinemia

     • MCL

     • CLL

   • Brand name: Brukinsa

4. Pirtobrutinib

   • Non-covalent, reversible BTK inhibitor

   • Effective against Cys481 mutations

   • Approved for:

     • Relapsed/refractory mantle cell lymphoma (after covalent BTKi failure)

   • Brand name: Jaypirca

---

3. Investigational and Emerging BTK Inhibitors

1. Orelabrutinib – Approved in China for B-cell malignancies; under global investigation

2. Tirabrutinib – Investigated for primary CNS lymphoma

3. Fenebrutinib – Non-covalent; being tested for autoimmune diseases like multiple sclerosis

4. Evobrutinib – Phase III trials in multiple sclerosis

5. Remibrutinib – Studied for allergic conditions, urticaria, and MS

---

4. Clinical Indications

BTK inhibitors are primarily used in hematologic oncology and, increasingly, in immune-mediated diseases.

Oncology indications include:

• Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)

• Mantle cell lymphoma (MCL)

• Waldenström macroglobulinemia (WM)

• Marginal zone lymphoma (MZL)

• Follicular lymphoma (under investigation)

• Primary CNS lymphoma (under investigation)

Autoimmune and inflammatory indications include:

• Rheumatoid arthritis (RA)

• Systemic lupus erythematosus (SLE)

• Multiple sclerosis (MS)

• Sjögren’s syndrome

• Chronic spontaneous urticaria (CSU)

---

5. Pharmacokinetics

Ibrutinib

• Bioavailability: ~3.9% (increases with food)

• Tmax: 1–2 hours

• Half-life: 4–6 hours

• Metabolism: CYP3A4

• Elimination: Feces

Acalabrutinib

• Bioavailability: Moderate

• Tmax: 0.5–1 hour

• Half-life: 1–2 hours

• Active metabolite: ACP-5862

• Metabolism: CYP3A4

Zanubrutinib

• Tmax: 2 hours

• Half-life: ~4 hours

• Metabolism: CYP3A

• High tissue penetration

Pirtobrutinib

• Tmax: 1–2 hours

• Half-life: ~20 hours

• Metabolism: CYP3A4

• Maintains efficacy despite C481S mutation

---

6. Mechanisms of Resistance

1. BTK C481S Mutation

   • Alters binding site, reducing efficacy of covalent inhibitors like ibrutinib

2. PLCγ2 Mutations

   • Bypass BTK signaling, activating downstream targets

3. CLL Subclonal Evolution

   • Resistant clones emerge under BTK inhibitor pressure

4. Upregulation of Alternate Pathways

   • PI3K-AKT or SYK signaling

5. Microenvironmental Support

   • Tumor cells depend on stromal cell interactions

Non-covalent inhibitors like pirtobrutinib are designed to overcome the C481S resistance mutation.

---

7. Adverse Effects

Common:

• Diarrhea

• Fatigue

• Nausea

• Rash

• Headache

• Arthralgia

Cardiovascular:

• Atrial fibrillation (especially ibrutinib)

• Hypertension

Hematologic:

• Neutropenia

• Thrombocytopenia

• Anemia

Infections:

• Increased risk of bacterial, fungal, and viral infections due to B-cell suppression

Other:

• Hemorrhage (via platelet dysfunction)

• Secondary malignancies (e.g., skin cancer)

---

8. Dosage Considerations

Ibrutinib

• 420 mg once daily for CLL

• 560 mg once daily for MCL

Acalabrutinib

• 100 mg twice daily

• Often combined with obinutuzumab in CLL

Zanubrutinib

• 160 mg twice daily or 320 mg once daily

Pirtobrutinib

• 200 mg once daily

Dose adjustments are necessary in cases of:

• Hepatic impairment

• Concomitant use with CYP3A4 inhibitors or inducers

---

9. Contraindications

Absolute contraindications:

• Known hypersensitivity to the drug or excipients

• Active bleeding disorders (relative)

Caution:

• Severe hepatic impairment

• History of arrhythmia

• Uncontrolled hypertension

• Concurrent use of anticoagulants

---

10. Precautions

• Monitor ECG in patients with cardiac history (due to atrial fibrillation risk)

• Assess infection risk and consider prophylaxis in high-risk patients

• Avoid grapefruit juice (CYP3A4 interaction)

• Monitor complete blood counts periodically

• Avoid live vaccines during treatment

• Consider secondary malignancy risk and recommend skin exams

---

11. Drug Interactions

CYP3A4 interactions:

• Inhibitors (increase drug levels):

  • Ketoconazole, ritonavir, clarithromycin

  • May necessitate dose reduction

• Inducers (decrease efficacy):

  • Rifampin, phenytoin, carbamazepine

  • Avoid co-administration

Anticoagulants/antiplatelets:

• Increased bleeding risk

• Use with caution and avoid dual therapy if possible

Proton Pump Inhibitors (PPIs):

• Reduce absorption of acalabrutinib

• Use H2 blockers or antacids instead

---

12. Future Directions and Pipeline Research

• Central Nervous System (CNS) Penetration:
  Zanubrutinib and tirabrutinib show promise for CNS lymphomas

• Combination Therapy:
  BTK inhibitors are being evaluated in combination with BCL-2 inhibitors (e.g., venetoclax), PI3K inhibitors, and anti-CD20 antibodies

• Next-Generation Non-covalent Inhibitors:
  Address resistance mutations and broaden spectrum

• Autoimmune Disease Focus:
  Fenebrutinib, remibrutinib, and evobrutinib are being developed for multiple sclerosis and systemic lupus erythematosus

---

13. Summary of Key BTK Inhibitors

Generic Name	Brand Name	Type	Approved Indications
Ibrutinib	Imbruvica	Covalent	CLL, MCL, WM, cGVHD, MZL
Acalabrutinib	Calquence	Covalent	CLL, MCL
Zanubrutinib	Brukinsa	Covalent	CLL, MCL, WM
Pirtobrutinib	Jaypirca	Non-covalent	R/R MCL after prior BTKi
Tirabrutinib	–	Covalent	Under investigation for CNS lymphoma
Fenebrutinib	–	Non-covalent	Autoimmune diseases (RA, SLE, MS)
Evobrutinib	–	Covalent	MS (Phase III trials ongoing)
Remibrutinib	–	Covalent	CSU, MS (under investigation)
Orelabrutinib	InnoCare	Covalent	Approved in China (CLL, MCL, WM)